Literature DB >> 7518279

RNA present in post-ribosomal supernatants makes ribosomes susceptible to inactivation by gelonin and alpha-sarcin.

M Brigotti1, D Carnicelli, S Sperti, L Montanaro.   

Abstract

The remarkable resistance of isolated ribosomes to gelonin is overcome by cofactors present in post-ribosomal supernatants. In rat liver post-ribosomal supernatant RNA is the cofactor responsible of the sensitization of ribosomes. Isolated RNA, which consists mostly of deacylated tRNA, accounts for less than 10 per cent of the activity of the original supernatant. The activity of the supernatant is completely destroyed by micrococcal nuclease and RNAase A and also by proteinase K, suggesting that some protein enhances the effect of RNA. RNA has a role also in the sensitization of ribosomes to alpha-sarcin, an RNAase which inactivates ribosomes by hydrolyzing a single phosphodiester bond in the same region of 28S rRNA which is the target of the N-glycosidase activity of gelonin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518279

Source DB:  PubMed          Journal:  Biochem Mol Biol Int        ISSN: 1039-9712


  3 in total

1.  Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.

Authors:  Xiaoxia Wen; Mi-Ae Lyu; Rui Zhang; Wei Lu; Qian Huang; Dong Liang; Michael G Rosenblum; Chun Li
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

2.  3'-immature tRNA(Trp) is required for ribosome inactivation by gelonin,a plant RNA N-glycosidase.

Authors:  M Brigotti; D Carnicelli; P Alvergna; A Pallanca; R Lorenzetti; M Denaro; S Sperti; L Montanaro
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

3.  Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.

Authors:  R R French; C A Penney; A C Browning; F Stirpe; A J George; M J Glennie
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.